![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Division of Pharmacology, Department of Neuroscience, School of Medicine, Federico II University of Naples, Naples, Italy
The aim of the present study was to investigate whether KV3.4 channel subunits are involved in neuronal death induced by neurotoxic
-amyloid peptides (A
). In particular, to test this hypothesis, three main questions were addressed: 1) whether the A
peptide can up-regulate both the transcription/translation and activity of KV3.4 channel subunit and its accessory subunit, MinK-related peptide 2 (MIRP2); 2) whether the increase in KV3.4 expression and activity can be mediated by the nuclear factor-
B (NF-
B) family of transcriptional factors; and 3) whether the specific inhibition of KV3.4 channel subunit reverts the A
peptide-induced neurodegeneration in hippocampal neurons and nerve growth factor (NGF)-differentiated PC-12 cells. We found that A
1–42 treatment induced an increase in KV3.4 and MIRP2 transcripts and proteins, detected by reverse transcription-polymerase chain reaction and Western blot analysis, respectively, in NGF-differentiated PC-12 cells and hippocampal neurons. Patch-clamp experiments performed in whole-cell configuration revealed that the A
peptide caused an increase in IA current amplitude carried by KV3.4 channel subunits, as revealed by their specific blockade with blood depressing substance-I (BDS-I) in both hippocampal neurons and NGF-differentiated PC-12 cells. The inhibition of NF-
B nuclear translocation with the cell membrane-permeable peptide SN-50 prevented the increase in KV3.4 protein and transcript expression. In addition, the SN-50 peptide was able to block A
1–42-induced increase in KV3.4 K+ currents and to prevent cell death caused by A
1–42 exposure. Finally, BDS-I produced a similar neuroprotective effect by inhibiting the increase in KV3.4 expression. As a whole, our data indicate that KV3.4 channels could be a novel target for Alzheimer's disease pharmacological therapy.
Address correspondence to: Dr. Lucio Annunziato, Division of Pharmacology, Department of Neuroscience, School of Medicine, University of Naples Federico II, Building 19, Via Pansini 5, 80131 Naples, Italy. E-mail: lannunzi{at}unina.it
Related articles in MolPharm:
This article has been cited by other articles:
![]() |
E. Choi and G. W. Abbott The MiRP2-Kv3.4 Potassium Channel: Muscling In on Alzheimer's Disease Mol. Pharmacol., September 1, 2007; 72(3): 499 - 501. [Abstract] [Full Text] [PDF] |
||||